Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 2:285–289

Article  CAS  Google Scholar 

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

Article  PubMed  CAS  Google Scholar 

Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

Article  PubMed  CAS  Google Scholar 

Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

Article  PubMed  CAS  Google Scholar 

Seeman E, Martin TJ (2015) Co-administration of antiresorptive and anabolic agents: a missed opportunity. J Bone Miner Res 30:753–764

Article  PubMed  CAS  Google Scholar 

Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511

Article  PubMed  CAS  Google Scholar 

Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838–1845

Article  PubMed  CAS  Google Scholar 

Hayat S, Magrey MN (2020) Glucocorticoid-induced osteoporosis: insights for the clinician. Clevel Clin J Med 87:417–426

Article  Google Scholar 

Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

Article  PubMed  Google Scholar 

Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 41:595–611

Article  PubMed  PubMed Central  Google Scholar 

Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Investig 102:274–282

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

Article  PubMed  CAS  Google Scholar 

Yao W, Dai W, Jiang L, Lay EYA, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE (2016) Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 27:283–294

Article  PubMed  CAS  Google Scholar 

Mok CC Romosozumab versus denosumab for osteoporosis in long-term glucocorticoid users (NCT04091243). ClinicalTrialsgov

Tsai JN, Lee H, David NL, Eastell R, Leder BZ (2019) Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol 7:767–775

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thiele S, Hannemann A, Winzer M, Baschant U, Weidner H, Nauck M, Thakker RV, Bornhäuser M, Hofbauer LC, Rauner M (2019) Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocr Connect 8:923–934

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jacobsson M, van Raalte DH, Heijboer AC, den Heijer M, de Jongh RT (2020) Short-term glucocorticoid treatment reduces circulating sclerostin concentrations in healthy young men: a randomized, placebo-controlled, double-blind study. JBMR Plus 4:e10341

Article  PubMed  PubMed Central  CAS  Google Scholar 

Beier EE, Sheu T-J, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA, Puzas JE (2017) Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Research 5:17013

Article  PubMed  CAS  Google Scholar 

Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD (2021) Understanding and managing corticosteroid-induced osteoporosis. Open Access Rheumatol 13:177–190

Article  PubMed  PubMed Central  Google Scholar 

Adami G, Pedrollo E, Rossini M, Fassio A, Braga V, Pasetto E, Pollastri F, Benini C, Viapiana O, Gatti D (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus 8:ziae016

Article  PubMed  Google Scholar 

England BR, Thiele GM, Anderson DR, Mikuls TR (2018) Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 361:k1036

Article  PubMed  Google Scholar 

Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G (2020) Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol 18:549–565

Article  PubMed  CAS  Google Scholar 

Laurent MR, Goemaere S, Verroken C, Bergmann P, Body J-J, Bruyère O, Cavalier E, Rozenberg S, Lapauw B, Gielen E (2022) Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian bone club. Front Endocrinol 13:908727

Article  Google Scholar 

Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899

Article  PubMed  Google Scholar 

Gulyás K, Horváth Á, Végh E et al (2020) Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39:167–175

Article  PubMed  Google Scholar 

Juhász B, Gulyás K, Horváth Á et al (2021) Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. BMC Musculoskelet Disord 22:817

Article  PubMed  Google Scholar 

Leder BZ (2018) Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus 2:62–68

Article  PubMed  Google Scholar 

Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243–1256

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 68:1013–1018

Article  PubMed  CAS  Google Scholar 

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

Article  PubMed  CAS